Eli Lilly and Company (LLY)vsP3 Health Partners Inc (PIII)
LLY
Eli Lilly and Company
$1,208.12
+7.13%
HEALTHCARE · Cap: $1.01T
PIII
P3 Health Partners Inc
$10.68
+9.65%
HEALTHCARE · Cap: $2.18B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 4807% more annual revenue ($72.25B vs $1.47B). LLY leads profitability with a 35.0% profit margin vs -8.6%. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
PIII
Avoid34
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 34.6x book value
3.5% revenue growth
0.0% earnings growth
Operating margin of 2.1%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : PIII
The strongest argument for PIII centers on Debt/Equity.
Bear Case : LLY
The primary concerns for LLY are PEG Ratio, Debt/Equity, P/E Ratio. A P/E of 40.2x leaves little room for execution misses.
Bear Case : PIII
The primary concerns for PIII are Revenue Growth, EPS Growth, Operating Margin.
Key Dynamics to Monitor
LLY profiles as a growth stock while PIII is a turnaround play — different risk/reward profiles.
PIII carries more volatility with a beta of 1.60 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 34/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →P3 Health Partners Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
P3 Health Partners Inc (PIII) is a pioneering healthcare organization focused on improving care quality and reducing costs through innovative, data-driven strategies. The company utilizes telehealth technologies and advanced analytics to provide customized healthcare solutions, particularly to underserved communities, and operates a comprehensive network of primary care providers and specialists. As a leader in value-based care models, P3 partners with community organizations to address the increasing demand for efficient healthcare services. With its strong dedication to delivering high-quality, cost-effective care, PIII is strategically positioned to succeed in the rapidly changing healthcare landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?